Bris­tol-My­ers part­ners with En­terome on a gut-lev­el ap­proach to im­muno-on­col­o­gy; Mor­phoSys adds $126M

Bris­tol-My­ers Squibb has turned to Paris-based mi­cro­bio­me ex­pert En­terome for its lat­est im­muno-on­col­o­gy part­ner­ship. The biotech land­ed a $15 mil­lion up­front and un­spec­i­fied, re­search sup­port and mile­stones to be­gin work on new bio­mark­ers and ther­a­peu­tics for can­cer. Bris­tol-My­ers is look­ing to the gut for new in­sights in­to the way the mi­cro­bio­me in­flu­ences re­sis­tance and re­sponse to im­munother­a­pies, like its block­buster check­point Op­di­vo. “En­terome’s fo­cus on tar­get iden­ti­fi­ca­tion and val­i­da­tion along with their sig­nif­i­cant ex­pe­ri­ence in mi­cro­bio­me re­search can help to ad­vance our goal to im­prove out­comes for pa­tients treat­ed with im­munother­a­pies,” said Carl De­ci­c­co, head of dis­cov­ery at Bris­tol-My­ers Squibb.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER